Malaria-specific antibody subclasses in immune individuals: A key source of information for vaccine design

Trends in Immunology

Volumn 24, Issue 1, 2003, Pages 30-35

  Garraud, Olivier ^a   Mahanty, Siddhartha ^b   Perraut, Ronald ^c  

^a UNIVERSITÉ JEAN MONNET   (France)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c INSTITUT PASTEUR DE DAKAR   (Senegal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD4 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN M; MALARIA VACCINE; MEMBRANE ANTIGEN; MEROZOITE SURFACE ANTIGEN 2; MEROZOITE SURFACE ANTIGEN 3; UNCLASSIFIED DRUG;

AFRICA; ANTIBODY RESPONSE; CELLULAR IMMUNITY; DISEASE TRANSMISSION; DRUG SCREENING; HUMORAL IMMUNITY; IMMUNE STATUS; IMMUNE SYSTEM; IN VITRO STUDY; MALARIA FALCIPARUM; NONHUMAN; PARASITE CONTROL; PARASITE TRANSMISSION; PARASITISM; PLASMODIUM FALCIPARUM; REVIEW;

EID: 0037213611     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4906(02)00012-1     Document Type: Article

References (53)

1. Greenwood B. What can the residents of malaria endemic countries do to protect themselves? Parassitologia. 41:1999;295-299.
2. Rogier C., et al. Plasmodium falciparum clinical malaria: lessons from longitudinal studies in Senegal. Parassitologia. 41:1999;255-259.
3. Smith T., et al. Premunition in Plasmodium falciparum infection: insights from the epidemiology. Trans. R. Soc. Trop. Med. Hyg. 93:((Suppl. 1)):1999;59-64.
4. Plebanski M., Hill A.V.S. The immunology of malaria. Curr. Opin. Immunol. 12:2000;437-441.
5. Luty A.J., et al. Interferon-γ responses are associated with resistance with Plasmodium falciparum in young African children. J. Infect. Dis. 179:1999;980-988.
6. Bouharoun-Tayoun H., et al. Mechanisms underlying the monocyte-mediated antibody killing of Plasmodium falciparum asexual blood stages. J. Exp. Med. 182:1995;409-418.
7. Carvalho L.J., et al. Malaria vaccine: candidate antigens, mechanisms, constraints and prospects. Scand. J. Immunol. 56:2002;327-343.
8. Manis J.P., et al. Mechanisms and control of class switch recombination. Trends Immunol. 23:2002;31-39.
9. Bolad A., Berzins K. Antigenic diversity of Plasmodium falciparum and antibody-mediated parasite neutralization. Scand. J. Immunol. 52:2000;233-259.
10. Konate L., et al. Variation of Plasmodium falciparum msp1 and msp2 allele prevalence and infection complexity in two neighbouring Senegalese villages with different transmission conditions. Trans. R. Soc. Trop. Med. Hyg. 93:1999;21-28.
11. Perraut R., et al. Evaluation of anti-P. falciparum antibodies in Senegalese adults using different types of crude extracts and recombinant antigens. Microbes Infect. 4:2002;31-35.
12. Druihle P., et al. A primary malarial infection is composed of a very wide range of genitically diverse but related mechanisms. J. Clin. Invest. 101:1998;2008-2016.
13. Aribot G., et al. Pattern of immunoglobulin isotype response to Plasmodium falciparum blood-stage antigens in individuals living in a holoendemic area of Senegal (Dielmo, West-Africa). Am. J. Trop. Med. Hyg. 54:1996;449-457.
14. Druilhe P., et al. In vivo veritas: lessons from immunoglobulin transfer experiments in malaria patients. Ann. Trop. Med. Parasitol. 91:1997;S37-S53.
15. Bouharoun-Tayoun H., Druilhe P. Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity. Infect. Immun. 60:1992;1473-1481.
16. Rzepzyk C., et al. Humoral immune responses of Solomon islanders to the merozoite surface antigen 2 of Plasmodium falciparum show pronounced skewing towards antibodies of the immunoglobulin G3 subclass. Infect. Immun. 65:1997;1098-1100.
17. Taylor R.R., et al. IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. Am. J. Trop. Med. Hyg. 58:1998;406-413.
18. Oeuvray C., et al. Merozoite surface Protein-3: A malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood. 84:1994;1594-1602.
19. Troye-Blomberg M., et al. Immune regulation of protection and pathogenesis in Plasmodium falciparum infection. Parassitologia. 41:1999;131-138.
20. Branch O.H., et al. A longitudinal investigation of IgG and IgM antibody response to the merozoite surface protein-1 19-kilodalton domain of Plasmodium falciparum in pregnant women and infants: associations with febrile illness parasitaemia and anemia. Am. J. Trop. Med. Hyg. 58:1998;211-219.
21. Aucan C., et al. High Immunoglobulin G2 (IgG2) and low IgG4 levels are associated with human resistance to Plasmodium falciparum malaria. Infect. Immun. 68:2000;1252-1258.
22. Morell A., et al. Metabolic properties of IgG subclasses in man. J. Clin. Invest. 49:1970;673-680.
23. Jouin H., et al. Fixed, epitope-specific, cytophilic antibody response to the polymorphic bloc 2 domain of the Plasmodium falciparum merozoite surface antigen MSP1 in humans living in malaria endemic area. Eur. J. Immunol. 31:2001;539-550.
24. Cavanagh D.R., et al. Differential patterns of human immunoglobulin G subclass responses to distinct regions of a single protein, the merozoite surface protein 1 of Plasmodium falciparum. Infect. Immun. 69:2001;1207-1211.
25. Bull P.C., et al. Parasite antigens on the infected red surface are targets for naturally acquired immunity to malaria. Nat. Med. 4:1998;358-359.
26. Dodoo D., et al. Antibodies to variant antigens on the surfaces of infected erythrocytes are associated with protection from Ghanaian children. Infect. Immun. 69:2001;3713-3718.
27. Baruch D.I., et al. Immunization of Aotus monkeys with a functional domain of Plasmodium falciparum variant antigen induces protection against a lethal parasite line. Proc. Natl Acad. Sci. USA. 99:2002;3860-3865.
28. Rotman H.L., et al. Fc receptors are not required for antibody-mediated protection against lethal malaria challenge in a mouse model. J. Immunol. 161:1998;1908-1912.
29. Cavinato R.A., et al. Susceptibility of the different development stages of the asexual (schizogonic) erythrocyte cycle of Plasmodium chabaudi chabaudi to hyperimmune serum, immunoglobulin (Ig)G1, IgG2a and F(ab)′ fragments. Parasite Immunol. 23:2001;587-597.
30. 19. Infect. Immun. 68:2000;2102-2109.
31. Clark M.R. IgG effector mechanisms. Chem. Immunol. 65:1997;88-110.
32. Vieira P., Rajewsky K. The half lifes of serum immunoglobulins in adult mice. Eur. J. Immunol. 18:1988;313-316.
33. Stavnezer J. Antibody class switching. Adv. Immunol. 61:1996;79-146.
34. Holder A.A., Riley E.M. Human humoral response to MSP-1. Parasitol. Today. 12:1996;173-174.
35. Egan A.F., et al. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP1. J. Infect. Dis. 173:1996;765-769.
36. Nguer C.M., et al. Plasmodium falciparum- and merozoite surface protein 1-specific antibody isotype balance in immune Senegalese adults. Infect. Immun. 65:1997;4873-4876.
37. 19: a study in immune adults living in areas of Plasmodium falciparum transmission. Am. J. Trop. Med. Hyg. 64:2001;204-206.
38. Groux H., et al. Functional characterization of the antibody-mediated protection against blood stages of Plasmodium falciparum in the monkey Saimiri sciureus. Eur. J. Immunol. 20:1990;2317-2323.
39. 19 over time in immune adult Senegalese. Am. J. Trop. Med. Hyg. 66:2002;137-139.
40. Garraud O., Nutman T.B. The role of cytokines in human B-cell differentiation into immunoglobulin-secreting cells. Bull. Inst. Pasteur. 94:1996;285-309.
41. 19 antigen. Immunology. 97:1999;204-210.
42. Remoué F., et al. Gender-dependent specific immune response during chronic human Schistosomiasis haematobia. Clin. Exp. Immunol. 124:2001;62-68.
43. Béniguel L., et al. Differential production in vitro of antigen specific IgG1, IgG3 and IgA: a study in Schistosoma haematobium-infected individuals. Parasite Immunol. 2002;. in press.
44. McNeela E.A., Mills K.H. Manipulating the immune system: humoral versus cell-mediated immunity. Adv. Drug Deliv. Rev. 51:2001;43-54.
45. Simms J.R. Large-scale comparison of experimental adjuvants with herpes simplex virus vaccine reveals a correlation of protection with IgG2a and IgG2b responses. J. Med. Virol. 68:2002;82-91.
46. Near K.A. Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminum hydroxide gel in a murine malaria vaccine model. Infect. Immun. 70:2002;692-701.
47. Garraud O., et al. Regulation of antigen-specific IgG subclasses to conserved and polymorphic Plasmodium falciparum antigens: an in vitro model. Infect. Immun. 70:2002;2820-2827.
48. + B lymphocytes from Plasmodium falciparum-immune West Africans. Scand. J. Immunol. 54:2001;606-612.
49. King C.L., et al. Acquired immune responses to Plasmodium falciparum merozoite surface protein-1 in the human fetus. J. Immunol. 168:2002;356-364.
50. Taylor R.R., et al. Selective recognition of malaria antigens by human serum antibodies is not genetically determined but demonstrates some features of clonal imprinting. Int. Immunol. 8:1996;905-915.
51. AlYaman F., et al. Reduced risk of clinical malaria in children infected with multiple clones of Plasmodium falciparum in a highly endemic area. A prospective community study. Trans. R. Soc. Trop. Med. Hyg. 91:1997;602-605.
52. Kashala O., et al. Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide SPf66 combined with the immunological adjuvant QS-21. Vaccine. 20:2002;2263-2277.
53. Good M., et al. Pathways and strategies for developing a malaria blood-stage vaccine. Annu. Rev. Immunol. 16:1998;57-87.